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Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet
drug is implicated. In the present study, the prevalence of single nucleotide poly-
morphisms of MDR1 (C3435T), CYP2C19 [CYP2C19*2 CYP2C19*3, CYP2C19*17] and P2Y12
(i-T744C) in Indian population and their effects on clopidogrel response was analyzed.
Methods and results: To analyze the prevalence of polymorphisms, 102 healthy individuals
were recruited. Clopidogrel response was assessed by ADP induced platelet aggregation in
clopidogrel naı¨ve acute myocardial infarction (AMI) patients (n ¼ 26) screened from 100 AMI
cases, before loading dose of 300 mg, at 24 h before next dose and 6 days after on 75 mg per
day and platelet aggregation inhibition (PAI) was calculated between these time intervals.
Genotyping was carried out by PCR-based restriction enzyme digestion method for C3435T
of MDR1 and i-T744C of P2Y12, by multiplex PCR for CYP2C19*2 (G681A) and CYP2C19*3
(G636A) and by nested PCR for CYP2C19*17 (C806T). The effect of the above mentioned
genetic variations on PAI was analyzed. Variant allele of CYP2C19*3 was not observed while
the prevalence of 3435T of MDR1 (0.524), CYP2C19*2 (681A, 0.352); i-744C of P2Y12 (0.088), as
well as wild type allele CYP2C19*17 (C806, 0.897) associated with decrease clopidogrel
response were observed. Trend toward poor response to clopidogrel was observed at 24 h
with the variant genotypes of CYP2C19*2 and i-T744C of P2Y12 as compared to wild type.
Conclusion: The present study did show a trend toward impaired response of clopidogrel to
inhibit platelet aggregation with variant genotypes of CYP2C19*2 and iT744C of P2Y12
compared to respective wild type genotype at 24 h.
Copyright ª 2013, Cardiological Society of India. All rights reserved.6308/387; fax: þ91 (0) 22 66106212.
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 5 8e1 6 7 1591. Background comprises of variations 139T, 744C and presence of i-ins801AIt has become extensively clear over the past decade that mil-
lions of lociwithin thehumangenomecan vary fromperson to
person which affect gene and subsequent protein expression
and influence our metabolism. Among our many happening
metabolicprocesses, theactionofdrug isdependentonvarious
metabolic processes that includes its activation and meta-
bolism; thus determining its efficacy. For a drug like clopidog-
rel, a highly prescribed antiplatelet agent, a genetic testing
which is able to predict variability in drug response has found
its place in the field of pharmacogenomics.
Clopidogrel, alone or combined with aspirin, is routinely
used to treat patients with a variety of vascular disorders. It is
a thienopyridine derivative; a prodrug activated in the liver by
cytochrome P450 (CYP) enzymes mainly by CYP2C19. This
active metabolite of the drug then binds irreversibly to the
platelet adenosine diphosphate (ADP) receptor P2Y12 which
inhibits platelet degranulation, glycoprotein IIb/IIIa (GPIIbIIIa)
receptor activation and thus platelet aggregation.1e3 The
pharmacodynamic response to clopidogrel varies widely from
subject to subject, and about 25% of patients treated with
standard clopidogrel doses display low ex vivo inhibition of
ADP-induced platelet aggregation. Generally patients with
<30% inhibition of platelet aggregation in response to clopi-
dogrel are considered weak responders to the antiplatelet
treatment while those with <10% are considered as resistant
to its effect.4,5
This poor response to clopidogrel is associated with an
increased risk of recurrent ischemic events. The mechanisms
underlying clopidogrel resistance are unclear. In addition to
non-adherence to treatment, poor bioavailability, accelerated
platelet turnover; certain genetic factors have been demon-
strated to be associated with this phenomenon. The single
nucleotide polymorphisms (SNPs) of Multidrug Resistance
Protein 1 (MDR1), CYP2C19, and P2Y12 genes are proposed
which influence the response to clopidogrel.6,7 MDR1 encodes
a drug-efflux transporter called P-glycoprotein which func-
tions as a physiologic intestinal barrier against drug absorp-
tion.8 The best studied polymorphism in this gene is a
transversion of C to T at position 34359,10 associated with
decreased expression. CYP2C19 of cytochrome P450 iso-
enzymes system is the predominant enzyme involved in clo-
pidogrel metabolic activation that carries out 45% of the first
step in the biotransformation of clopidogrel.11 Genetic varia-
tions of this enzyme are CYP2C19*1 wild type, CYP2C19*2,
[G681A] with splicing defect, and CYP2C19*3 [G636A] with stop
codon. CYP2C19*2 and CYP2C19*3 comprises about 95% of the
poor metabolizer type.12e16 In contrast, an allelic variant re-
ported as CYP2C19*17 (C806T; 50-flanking region of the gene),
has been associated with increased enzyme function.17,18
P2Y12 belongs to the Gi class of a group of G protein-coupled
(GPCR) purinergic receptors and is a chemoreceptor for
ADP.19 Two functional haplotypes of P2Y12 designated as H1
and H2, tagged by 4 SNPs in absolute linkage disequilibrium
(i-C139T, i-T744C, i-ins801A, G52T) have been identified. H1
haplotype is the one showing a ‘C’ in position 139 of intron 1, a
‘T’ in position 744 of intron 1, absence of ‘i-ins801A’ in intron 1,
as well as a ‘G’ in position 52 of exon 2. H2 haplotypein intron 1 along with 52T of exon 2. Of these two haplotypes,
haplotype (H2) has been reported to be associated with
enhanced platelet reactivity.20
In addition, it has been observed that the genotypic fre-
quencies ofMDR1,CYP2C19 and P2Y12 polymorphisms present
some degree of variations among different ethnic groups. As a
result, the prevalence of the predicted metabolic phenotypes
associated with these polymorphisms may vary significantly
among different world-wide populations. Indians have been
documented to have high 3435T allele frequency (0.61e0.62) as
compared to the C3435 allele of MDR1.21,22 For Indian popu-
lation Adithan et al23 have specifically documented the fre-
quency of CYP2C19*1, *2 and *3 alleles as 0.598 (59.8%), 0.379
(37.9%) and 0.022 (2.2%), respectively for Tamilians (n ¼ 112)
and 0.703 (70.3%), 0.297 (29.7%) and 0 for North Indians
(n ¼ 121), respectively. Another study by Panchabhai et al24
have evaluated the poor and extensive metabolizer type of
CYP2C19 enzyme activity by analyzing the drug metabolite in
blood. Their study population was Gujarati and Marwadi
living in Mumbai. It was seen that 10.36% of this population
were poor metabolizers (PM) whereas 89.63% were extensive
metabolizers (EM). The prevalence as per CYP2C19*2 or *3 was
not carried out in this study. In fact, it was suggested that a
genotyping evaluation would better help in individualize drug
therapy. Moreover, pharmacogenetic testing is more in de-
mand since the inclusion of an FDA “black box” warning
recommending genetic testing prior to prescription of
clopidogrel.25
Therefore, the aim of the present study was to analyze
the prevalence of the variant genotypes of the above said
polymorphisms i.e. C3435T of MDR1, CYP2C19*2 (G681A),
CYP2C19*3 e (G636A) and CYP2C19*17 (C806T) as well as
i-T744C of P2Y12, and analyze their effect on the antiplatelet
activity of standard-dose of clopidogrel assessed by ex vivo
ADP induced platelet aggregation.2. Material and methods
2.1. Study population
The study population included 102 healthy individuals and 26
acute myocardial infarction (AMI) patients. These subjects
were Maharashtrian, Gujarati and Marwadi in decreasing
number representing theWestern region of India based out of
Mumbai.
The healthy individuals included were volunteers in the
study, recruited for genotyping of these polymorphisms. They
were with systolic blood pressure/diastolic blood pressure
(SBP/DBP) ¼ 135/85 mmHg or less, with no clinical symptoms
of any other organic disease. Their blood samplewas collected
after an overnight, 12 h fast. The subjects having fasting
glucose levels >110 mg/dL, serum transaminases, Blood Urea
Nitrogen (BUN), Creatinine levels and lipid profile beyond
normal range, abnormal ECGs and abnormal Carotid Doppler
were excluded from the control group. These criteria are fol-
lowed for including healthy individuals under controls. They
form a part of our study population to analyze the overall
Table 1 e Primers sequence.
Gene Primer sequence
MDR131
(C3435T)
50 TGT TTT CAG CTG CTT GAT GG 30
50 AAG GCA TGT ATG TTG GCC TC 30
CYP2C19*233
(G681A)
50 CAG AGC TTG GCA TAT TGT ATC 30
50 GTA AAC ACA CAA CTA GTC AAT G 30
CYP2C19*333
(G636A)
50 AAA TTG TTT CCA ATC ATT TAG CT 30
50 ACT TCA GGG CTT GGT CAA TA 30
CYP2C19*1734
(C806T)
SET 1
50 GCC CTT AGC ACC AAA TTC TC 30
50 ATT TAA CCC CCT AAA AAA ACA CG 30
SET 2
50 AAA TTT GTG TCT TCT GTT CTC AAT G 30
50 AGA CCC TGG GAG AAC AGG AC 30
P2Y12
32
(i-T744C)
50 TCA CTT ATC TCT GGT GAA ATA AAA
AGA TTA CGT A 30
50 GTC AGA AAT GGC CTG TGT ATA TAT
GGT CAT GAG 30
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sample was also collected of randomly selected 10 healthy
individuals for platelet aggregation study.
To analyze the effect of these polymorphism on platelet
aggregation only those AMI cases (n ¼ 26) were selected and
recruited who were not on clopidogrel before and were pre-
scribed clopidogrel later. They were clopidogrel naı¨ve patients
screened from 100 AMI patients in the span of two years
(2009e2011). The platelet aggregation of these patients was
compared before and after the intake of the drug and thus
platelet aggregation inhibition (PAI) was calculated and the
effect of genotypes on PAI was analyzed. AMI patients were
those who suffered an AMI with prolonged chest pain more
than 30min and ST segment elevationmore than 0.1 mv on at
least two adjacent ECG leads with elevated cardiac enzymes
from ICCUward. These AMI patients werewith first episode of
chest pain and had neither past history of such clinical
symptoms nor were on any known medications for the same.
AMI patients on prior clopidogrel treatment at the time of
admission were excluded as their basal platelet aggregation
could not be obtained which was essential to compare the
extent of PAI after the intake of clopidogrel. Other exclusion
criteria were valvular heart disease, known cardiomyopathy,
malignancy, renal or liver diseases as well as subjects with
systemic inflammatory disease to exclude any other compli-
cations and keep the patient population homogenous. These
AMI patients at presentation were given 300 mg loading dose
of clopidogrel and aspirin (150 mg) along with the standard
treatment of nitrates antiarrhythmics, antifailures, statins
and proton pump inhibitors (PPI) and subsequently were on
maintenance dose of 75 mg clopidogrel per day. PPIs,
frequently used in patients receiving clopidogrel and aspirin,
are also metabolized by CYP2C19 and CYP3A4.7 In our study,
pantoprazole 40 was used as PPI for all the patients. In
contrast to the reported negative omeprazole-clopidogrel drug
interaction, the intake of pantoprazole or esomeprazole has
been demonstrated, not to interfere with the activation of
clopidogrel and was therefore not associated with impaired
response.26,27 The subjects were recruited in study only after
obtaining informed consent. Information regarding their de-
mographic status, clinical history, family history and medi-
cations were noted down in detail. The ethical committee of
Sir H. N. Hospital and Research Centre and Rajawadi Munic-
ipal Hospital approved the study protocol. The analyzes of the
samples were carried out at Sir H. N. Medical Research Society
at Sir H. N. Hospital and Research Centre, Mumbai.
2.2. Sample collection
Blood samples of 102 healthy individuals were collected in the
plain and EDTA anti-coagulated vacutainer after overnight,
12 h fast for analyzing biochemical parameters and complete
blood count respectively. Of these subjects, 10 healthy in-
dividuals were randomly selected and their blood sample was
also collected in Na-Citrate vacutainer (3.2%) for platelet ag-
gregation test. Peripheral blood samples of AMI patients were
collected at presentation for routine analysis such as elec-
trolytes, cardiac enzymes, complete blood count and pro-
thrombin time. Remaining serum was stored at 80 C and
EDTA blood sample at 4 C for further analysis. Peripheralblood of each AMI patient was collected in Na-Citrate vacu-
tainer (3.2%) for platelet aggregation test at three different
point of time e (1) baseline or 0 h e before clopidogrel loading
dose (300 mg) administration, (2) 24 h after loading dose
(300mg) administration and before the next dose of 75mg and
(3) at 6 days when the patient was on 75mgmaintenance dose
of clopidogrel.
2.3. Platelet aggregation by turbidometric method
Platelet aggregation testwascarriedoutat theearliermentioned
three different point of time within 4 h of blood collection.
Platelet rich plasma (PRP) and platelet poor plasma (PPP) were
separated from each Na-citrated blood and then the test was
carried out in duplicates using ADP (10 mM) as agonist in a two
chambered Chronolog Platelet Aggregometer (model 490-2D).
With the help of AggroLink software package, platelet aggrega-
tion was expressed as the maximal percent change in light
transmittance frombaseline inPRPwithPPPusedas a reference.
All the patients were administered aspirin along with clopidog-
rel. The predominant antiplatelet effect of aspirin is mediated
through its irreversible inactivation of cyclooxygenase (COX) 1,
which is responsible for the formation of thromboxane A2, a
potent vasoconstrictor and platelet aggregator, from arach-
idonic acid.27 In the present study, final concentration of 10 mM
ADP was chosen for platelet aggregation because at this con-
centration ADP induces complete platelet aggregation in a
manner independent of thromboxane A2 production.14,28,29
2.4. Genotyping of polymorphisms
DNA was extracted from peripheral leukocytes by modified
Miller et al’s salting out procedure.30 Genotyping was carried
out by polymerase chain reaction (PCR) e based restriction
enzyme digestion method for C3435T of MDR131 and i-T744C
of P2Y12.
32 A multiplex PCR was standardized for CYP2C19*2
and CYP2C19*3 using primer sequence of Pang et al33 while
CYP2C19*17 was genotyped using nested PCR.34 The primers
used for PCR of each polymorphism are given in Table 1. The
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Table 2. Taq polymerase and dNTPs were from Fermen-
taseMBI. PCR was carried out in thermal cycler “T Gradient”
from “Biometra” (Genetix Biotech Asia Pvt. Ltd.). Each sample
was run in duplicates with a positive and negative control for
each for a batch of samples. Amplified PCR product was then
run on Agarose gel electrophoresis. Finally, the PCR products
were subjected to restriction digestion with the enzymes Sau
3A1, Sma I, BamHI, Nsi I and Rsa I for identifying genotypes of
C3435T of MDR1, CYP2C19*2, CYP2C19*3, CYP2C19*17 and
i-T744C of P2Y12 respectively. Fig. 1 shows the restriction
digestion pattern of C3435T of MDR1, Fig. 2 shows CYP2C19*2
and CYP2C19*3 genotypes of multiplex PCR, Figs. 3 and 4 show
that of CYP2C19*17, and i-T744C of P2Y12, respectively on 10%
polyacrylamide gel electrophoresis.
2.5. Statistical analysis
Genotype frequencies were estimated by the gene-counting
method. Allelic frequencies were calculated from genotype
frequencies. Genotypes were tested for deviations from Har-
dyeWeinberg equilibrium. The change in platelet aggregation
within a group from baseline to 24 h or 6th day was assessed
using Wilcoxon Signed Rank test. The comparison of changeTable 2 e Details of the PCR protocol for genotyping polymorp
Genotype Content of the PCR reaction
MDR1 (C3435T) 1 U Taq DNA polymerase, 2.5 ml of 10X
Buffer with 25 mM MgCl2, 0.5 ml of 10 mM
dNTPs, 10 pmoles of primers and 100 ng
of genomic DNA
CYP2C19*2 and
CYP2C19*3
polymorphisms
by multiplex PCR
The 50 ml reaction mixture contained 2 U
Taq DNA polymerase, 5 ml 10X Buffer with
25 mM MgCl2, 1 ml 10 mM dNTPs and 15
pmoles of each specific primers and 100 ng
of genomic DNA
CYP2C19*17
polymorphism
by nested PCR
First PCR
The first 25 ml reaction mixture contained 1 U
Taq DNA polymerase, 2.5 ml of 10X buffer
with 25 mM MgCl2, 0.5 ml of 10 mM dNTPs
and 10 pmoles of each specific primers and
100 ng of genomic DNA
Second PCR
The next 50 ml reaction mixture contained 1U
Taq DNA polymerase, 5 ml of 10X Buffer with
25 mM MgCl2, 0.5 ml of 10 mM dNTPs and 10
pmoles of each specific primers. For each
sample to be genotyped 1 ml of earlier amplified
PCR product was added later.
P2Y12
(i-T744C)
2 U Taq DNA polymerase (Fermentas - MBI),
2.5 ml 10X Buffer with 25 mM MgCl2, 0.5 ml of
10 mM dNTPs and 10 pmoles of each specific
primers and 100 ng of genomic DNA.in platelet aggregation between groups was assessed by
ManneWhitney U test.3. Results
3.1. Characteristics of the study population
Demographic data and routine pathology data of 102 healthy
individuals and 26 AMI patients is given in Table 3 and Table 4
respectively. There was no significant difference in the age,
body mass index and blood pressure amongst AMI patients.
Six out of 26 patients were hypertensive while 4 were diabetic.
3.2. Allelic frequencies
The genotype and allele frequencies for all the poly-
morphisms studied are given in Table 5 and Table 6 for
healthy individuals and AMI patients, respectively. The study
population did not show the presence of the variant allele of
CYP2C19*3. The observed genotype distributions did not
deviate from HardyeWeinberg equilibrium.
As the sample size of healthy individuals (n ¼ 102) and that
of AMI patients (n ¼ 26) differed, the significance of differencehisms.
PCR conditions PCR amplified
product
Initial denaturation at 95 C for 5 min
followed by 30 cycles of denaturation
at 95 C for 45 s, annealing at 62 C
for 30 s and extension at 72 C for
30 s followed by final extension at
72 C for 5 min.
197 base pair (bp)
The PCR amplification conditions
consisted 3 steps e an initial
denaturation step at 95 C for 5 min
followed by 30 cycles of denaturation
at 95 C for 45 s, annealing at 58 C
for 50 s and extension at 72 C for 1
min followed by final extension at
72 C for 3 min
321 bp of CYP2C19*2
(G681A) and 271 bp of
CYP2C19*3 (G636A)
An initial denaturation step at 95 C
for 5 min followed by 30 cycles of
denaturation 95 C for 45 s, annealing
at 62 C for 30 s and denaturation at
72 C for 30 s followed by final
extension at 72 C for 5 min.
Second PCR
Initial denaturation step at 95 C for 5
min followed by 30 cycles of
denaturation at 95 C for 45 s,
annealing at 62 C for 30 s and
extension at 72 C for 30 s followed
by final extension at 72 C for 3 min
473bp
143bp
Initial denaturation step at 95 C for 5
min followed by 30 cycles of
denaturation at 95 C for 45 s,
annealing at 60 C for 2 min and
extension at 72 C for 2 min followed
by final extension at 72 C for 5 min
220bp
Fig. 3 e The restriction digestion pattern of CYP2C19*17 on
10% polyacrylamide gel electrophoresis. Lane 1: PCR
products of 143 bp. Lane 2: wild type genotype (*1 3 *1)
showing one band of 116 bp. Lane 3: Heterozygous
genotype (*1 3 *17) showing two bands 143 bp and 116 bp.
Lane 4 to 6: homozygous mutant genotype (*17 3 *17)
showing one band of 143 bp. Lane 7: O0 Range Ruler, 20 bp,
ready to use DNA Ladder from MBI Fermentas.
Fig. 1 e The restriction digestion pattern of MDR1 [C3435T]
on 10% polyacrylamide gel electrophoresis. Lane 1: PCR
product of 197 bp. Lane 2 and 4: heterozygous genotype
(C3435T) showing two bands of 197 bp and 158 bp. Lane 3:
O0 Range Ruler, 20 bp, ready to use DNA Ladder from MBI
Fermentas. Lane 4: homozygous mutant genotype
(T3435T) showing one band of 158 bp. Lane 6: wild type
genotype (C3435C) showing one band of 197 bp.
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statistics with Yates Corrections) was not calculated. How-
ever, it was observed that the prevalence of wild type allele
frequency of CYP2C19*17 (C806, 0.897 > 0.865) and the variantFig. 2 e The restriction digestion pattern of CYP2C19*2 and
CYP2C19*3 on 10% polyacrylamide gel electrophoresis.
Lane 1: PCR products of 321 bp and 271 bp for CYP2C19*2
and CYP2C19*3 respectively. Lane 2eLane 4: wild type
genotype (*1 3 *1) of CYP2C19*2 showing two bands 212 bp
and 109 bp and wild type genotype (*1 3 *1) of CYP2C19*3
showing two bands 175 bp and 196 bp. Lane 3:
Heterozygous genotype (*1 3 *2) of CYP2C19*2 showing
three bands 321 bp, 212 bp and 109 bp and wild type
genotype (*1 3 *1) of CYP2C19*3 showing two bands 175 bp
and 196 bp. Lane 4: homozygous mutant genotype (*2 3 *2)
showing one band of 321 bp and wild type genotype
(*1 3 *1) of CYP2C19*3 showing two bands 175 bp and 196
bp. Lane 5: O0 Range Ruler, 20 bp, ready to use DNA Ladder
from MBI Fermentas.allele frequency of 3435T of MDR1 (0.576 > 0.524), CYP2C19*2
(681A, 0.423 > 0.352) as well as i744C of P2Y12 (0.173 > 0.088) of
AMI patients although marginal, were more as compared that
of healthy individuals (Tables 5 and 6).
3.3. Platelet aggregation
The platelet aggregation of healthy individuals (n ¼ 10) was in
the range of 60e80% (70.4  8.87) almost similar to averageFig. 4 e The restriction digestion pattern of P2Y12 [i-T744C]
on 10% polyacrylamide gel electrophoresis. Lane 1: PCR
products of 220 bp. Lane 2: wild type genotype (i-T744T)
showing one band of 220 bp. Lane 3: heterozygous
genotype (i-T744C) showing two bands 220 bp and 196 bp.
Lane 4: Homozygous mutant genotype (i-C744C) showing
one band of 196 bp. Lane 5: O0 Range Ruler, 20 bp, ready to
use DNA Ladder from MBI Fermentas.
Table 3 e Demographic data.
Parameters Healthy individuals
(n ¼ 102)
AMI patients
(n ¼ 26)
M:F 47: 55 19:7
Age [years] 43.59  10.74 51  10
BMI [kg/m2] 24.4  4.53 23.98  2.12
SBP [mmHg] 118  9.23 135  29
DBP [mmHg] 78.96  6.73 82  17
Smoking 14 14
Alcohol consumption 15 8
Hypertension e 6
Diabetes mellitus e 4
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The platelet aggregation of all AMI patients (n¼ 26) dropped to
45.6% at 24 h subsequent to the administration of 300 mg
loading dose with PAI of only 23.56%. Further, platelet aggre-
gation dropped to 43.4% at 6 days on further 75 mg mainte-
nance dose per day of clopidogrel demonstrating PAI of only
25.76%.
Among 26 AMI patients, none demonstrated homozygous
mutant (T806T) genotype of CYP2C19*17. All the patients were
associated with either wild type or heterozygous genotypes
associated with decreased enzyme function. Also there were
only 4 patients eachwithwild type (C3435C) genotype ofMDR1
and rests were with variant genotypes associated decrease
intestinal absorption. Therefore, further analysis of effect of
polymorphisms on response to clopidogrel was carried out
with respect to CYP2C19*2 genotypes and patients were
grouped according to common genotypes as depicted in
Table 7. Group I, II and III were with wild type (G681G), het-
erozygous (G681A) and homozygousmutant (A681A) genotype
of CYP2C19*2 respectively and wild type genotype (i-T744T) of
P2Y12. Subsequently, subjects were grouped as per variant
genotypes of i-T744C of P2Y12. Group IV was one case having
homozygous mutant genotype (A681A) of CYP2C19*2 and
heterozygous genotype (i-T744C) of P2Y12 while three cases
with heterozygous genotype (G681A) of CYP2C19*2 and ho-
mozygous mutant genotype (i-C744C) of P2Y12 were includedTable 4 e Routine pathology data.
Parameters Healthy
individuals
(n ¼ 102)
AMI patients
(n ¼ 26)
Total cholesterol (TC) (mg/dl) 188.5  35.38 172.5  44.4
HDL-cholesterol (HDL-C) (mg/dl) 44.63  9.29 38.4  7.65
TC/HDL-C 4.31  0.86 4.47  0.74
LDL cholesterol (LDL-C) (mg/dl) 124.8  25.5 105.9  40.1
LDL-C/HDL-C 2.8  0.71 2.8  0.6
Triglycerides (mg/dl) 102.6  41.5 127.4  61.02
VLDL cholesterol (mg/dl) 22.24  13.11 25.5  12.2
Glucose (mg/dl) 95.1  10.1 154.2  68.3
SGOT U/L 16  3.25 51.4  30.12
SGPT U/L 20.1  2.3 38.2  15.8
BUN (mg/dl) 8.1  2.37 10.1  7.32
Creatinine (mg/dl) 0.7  0.12 0.98  0.24
Uric acid (mg/dl) 4.0  1.3 4.95  1.84
Total WBC count/mL 6975  1602 11 210  2926
Platelet count  103/mL 259  109.5 328  137in Group V. There was only one case with wild type genotype
(G681G) of CYP2C19*2 and homozygous mutant genotype
(i-C744C) of P2Y12 (Group VI). The PAI at 24 h was in the
decreasing order; 37%, 22%, 18.5%, 18.0%, 14.3% and 11.0% for
Group I, II, III, IV, V and VI respectively.
Statistical analysis of Group I and Group II with 6 and 13
cases, respectively demonstrated that decrease in platelet
aggregation i.e. PAI of Group I from 0 h to 24 h (37%, p ¼ 0.002)
and 0 to 6th day (27%, p¼ 0.027) was significant. The samewas
also observed for Group II for PAI from baseline to 24 h (22.0%,
p¼ 0.001) as well as from baseline to 6th day (24.3%, p¼ 0.001).
PAI at 24 h of Group II (22.0%) was less by 15% as compared to
Group I (37.0%) but this decrease in PAI did not reach statistical
significance of p< 0.05 (p ¼ 0.072). PAI at 6 days from baseline
of Group I and II were almost similar 27% and 24.3%, respec-
tively and did not reach statistical significance of p < 0.05
(p ¼ 0.639). There were 3 hypertensives and one diabetic pa-
tient in Group I while in Group II there were 2 hypertensives
and 2 diabetic patients. After excluding these patients, the
difference in the PAI between Group I and II was 16.0% almost
similar to that obtained on including these patients (15.0%).
There was no significant difference in the BMI or age between
the two patient groups (data not shown).
Table 7 also depicts the CYP2C19*17 and C3435T genotypes
ofMDR1. In Group I, out of 6 patients, 5 hadwild type genotype
(C806C) for CYP2C19*17 while just one showed heterozygous
genotype (C806T) for the same. Whereas in Group II, 11 out of
13 had wild type genotype for CYP2C19*17 and just 2 showed
heterozygous genotype for the same. On the other hand, in
Group I out of 6 patients 2 were heterozygous (C3435T) and 4
were homozygous mutant (T3435T) thus all were with variant
genotypes of C3435T polymorphism of MDR1. In Group II, out
of 13 patients, 7 were heterozygous and 3 each showed ho-
mozygousmutant andwild type genotype (C3435C) for C3435T
polymorphism of MDR1.
Remaining 7 patients could not be included in Group I or II
and therefore in Table 7 they are grouped separately. Their PAI
at 24 h was less as compared to Group I. Of these notably, 3
patients of Group V with not only heterozygous genotype for
CYP2C19*2 but also homozygousmutant genotype (i-C744C) of
P2Y12 demonstrated further (22.0%e14.3%) 7.7% less PAI as
compared to Group II at 24 h. One patient with wild type
genotype of CYP2C19*2 and homozygous mutant genotype
(i-C744C) of P2Y12 demonstrated only 11% PAI at 24 h. At 6th
day, the PAI for all seven patients was either similar or near to
Group I patients.4. Discussion
The present study demonstrated the prevalence of poly-
morphisms of drug-efflux transporter protein responsible for
drug absorption (MDR1), one of the metabolizing enzymes of
clopidogrel (CYP2C19) and its target (P2Y12), in our study
population. Its effect was demonstrated on antiplatelet ac-
tivity of clopidogrel in AMI patients assessed ex vivo by
ADP-induced platelet aggregation.
In our study population variant allele frequency of 3435T of
MDR1 affecting intestinal absorption was found to be 52.4%
(0.524) nearing to that reported for Indian population
Table 5 e Genotype and allele frequencies of healthy individuals (n[ 102) for all the polymorphisms studied.
Genotype frequency Allele frequency
Wild type Heterozygous Homozygous Wild type allele Mutant allele
MDR1
(C3435T)
26.4% (27) 42.1% (43) 31.4% (32) 3435C ¼ 0.475 3435T ¼ 0.524
CYP2C19*2
(G681A)
46% (47) 37% (38) 16.7% (17) 681G ¼ 0.647 681A ¼ 0.352
CYP2C19*3
(G636A)
100% (102) 0 0 636G ¼ 1.0 e
CYP2C19*17
(C806T)
81.4% (83) 16.7% (17) 1.96% (2) 806C ¼ 0.897 806T ¼ 0.102
P2Y12
(i-T744C)
85.2% (87) 11.8% (12) 2.94% (3) i744T ¼ 0.911 i744C ¼ 0.088
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1 5 8e1 6 7164(0.61e0.62).21,22 In African,35 Asian and Caucasian36 popula-
tion, allele frequency of 3435T ofMDR1has been reported to be
21.0%, 42.0% and 55.0%, respectively. The variant allele fre-
quency of CYP2C19*2 (681A) associated with poor metabolizer
type, was observed to be 35.2% (0.352) in the present study
which is similar to that reported by Adithan et al23 for
Tamilian population (37.9%) and Mizutani et al36 who have
reported 30e35% in Asians and is greater than reported for
African (17e20%)35 and Caucasians (13e18%).36 In the present
study, the presence of CYP2C19*3 variant allele (636A), also
associated with poor metabolizer type, was not observed
which has also been reported by Pang et al33 in Malaysian
subjects. However, Adithan et al22 have reported CYP2C9*3
variant allele frequency as 2.2% in Tamilian population. In
African,35 Asians and Caucasians,36 the variant allele fre-
quency of CYP2C19*3 has been reported to be<1%, 5e10% and
<1%, respectively. Our study population demonstrated low
variant allelic frequency of 10.2% (0.102) for CYP2C19*17which
in fact is associated with increased enzyme function. The
variant allelic frequency of CYP2C19*17 is reported to be 18%,
2e4% and 18e20% in African,35 Asian and Caucasian36 popu-
lation respectively. With respect to P2Y12 (i-T744C) poly-
morphism, although the prevalence of wild type allele was
maximum, variant allele associated with enhanced platelet
reactivity was also observed in our study population. The
frequency of i-744C variant allele of P2Y12 was 8.8% (0.088).
Thus, overall our study population was associated with low
response to clopidogrel with respect to the prevalence of wild
type allele (C806) frequency of 0.897 of CYP2C19*17 and variantTable 6 e Genotype and allele frequencies of AMI patients (n[
Genotype frequency
Wild type Heterozygous H
MDR1
(C3435T)
15.4% (04) 53.9% (14)
CYP2C19*2
(G681A)
27% (07) 61.5% (16)
CYP2C19*3
(G636A)
100% (26) 0
CYP2C19*17
(C806T)
73.1% (19) 26.9% (07)
P2Y12
(i-T744C)
80.7% (21) 3.8% (01)allele frequency ofMDR1 (3435T) of 0.524, CYP2C19*2 (681A) of
0.352 as well as P2Y12 (-i744C) of 0.088.
None of the AMI patient out of 26 demonstrated a combi-
nation of wild type genotype of MDR1 (C3435C), CYP2C19*2
(G681G), CYP2C19*3 (G636G), with heterozygous (C806T) or
homozygous (T806T) variant genotype of CYP2C19*17 as well
as wild type genotype (iT744T) of P2Y12 favoring good ab-
sorption, metabolization and effective action on target re-
ceptor of clopidogrel, respectively. This would explain overall
low PAI i.e. just 23.56% in the study population at 24 h after
clopidogrel administration which can be grouped under weak
responders to clopidogrel (<30%).
Although our entire study population did not demonstrate
CYP2C19*3 variant genotypes associated with poor metabo-
lizer type, with respect to CYP2C19*17 only 7 AMI patients
were heterozygous (C806T) associated with increased enzyme
function and rest were all withwild type allele associatedwith
normal enzyme function. Also there were only four AMI pa-
tients associated with wild type (C3435C) genotype of MDR1
with optimum absorption.
In the present study, a trend toward poor response to
clopidogrel with variant genotypes of CYP2C19*2 as opposed
to their wild type counterparts, as assessed ex vivo was
observed. These results of our study are similar to those of
Hulot et al,14 Brandt et al15 and Gusti et al37 who have
underlined the role of CYP2C19 polymorphisms in the clopi-
dogrel metabolic activation process. However, in contrast to
the study by Hulot et al14 our study didn’t find any significant
effect of CYP2C19*2 on PAI at 6th day when the AMI patients26) for all the polymorphisms studied.
Allele frequency
omozygous Wild type allele Mutant allele
30.8% (08) 3435C ¼ 0.423 3435T ¼ 0.576
11.5% (03) 681G ¼ 0.576 681A ¼ 0.423
0 636G ¼ 1.0 e
0 806C ¼ 0.865 806T ¼ 0.134
15.4% (04) i744T ¼ 0.826 i744C ¼ 0.173
Table 7 e Platelet aggregation, platelet aggregation inhibition (PAI) of AMI patients (n[ 26) grouped as per genotypes.
Groups Platelet
aggregation (%)
Platelet aggregation
inhibition (PAI) (%)
Genotypes
CYP2C19 P2Y12 CYP2C19 MDR 1
0 h 24 h 6 days At 0 h At 6 days *2 *3 -i T744C *17 C3435T
Group I (n ¼ 6) 67.8 30.7 40.3 37 27.3 W W W W HMM
W W W W HMM
W W W W HMM
W W W W HMM
W W W W HZ
W W W HZ HZ
Group II (n ¼ 13) 67.15 45.15 42.15 22 24 HZ W W W HZ
HZ W W W HZ
HZ W W W HZ
HZ W W W HMM
HZ W W W HZ
HZ W W HZ W
HZ W W W HMM
HZ W W W W
HZ W W W HMM
HZ W W HZ HZ
HZ W W W W
HZ W W W HZ
HZ W W W HZ
Group III (n ¼ 2) 71.5 53 51 18.5 20.5 HMM W W HZ HZ
HMM W W HZ HZ
Group IV (n ¼ 1) 79 61 47 18 32 HMM W HZ W HZ
Group V (n ¼ 3) 76.7 62.3 50 14.3 26.7 HZ W HMM HZ HMM
HZ W HMM HZ HZ
HZ W HMM W W
Group VI (n ¼ 1) 64 53 33 11 31 W W HMM W HZ
Wewild type genotype, HZeheterozygous genotype, HMMehomozygous mutant genotype.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1 5 8e1 6 7 165were on maintenance dose of 75 mg clopidogrel per day,
indicating that a part of low pharmacodynamic response of
clopidogrel due to the CYP2C19*2 polymorphism may be
reversed to some extent by repeated dosing.
Fontana et al20 have identified a P2Y12 receptor haplotype
H2 to be strongly associated with an increase in ADP-induced
platelet aggregation. In 2008, Malek et al32 reported that the
co-existence of the variant i-744C allele of P2Y12 and the
variant 681A allele of CYP2C19*2 is associated with persisting
platelet activity in patients with acute coronary syndrome
(ACS) on clopidogrel treatment. Similar to this finding, in the
present study, there were three patients with homozygous
mutant genotype (i-C744C) for P2Y12 receptor in combination
with heterozygous genotype for CYP2C19*2 (Group V) who
showed additional 7.7% decreased PAI as compared to pa-
tients of Group II with wild type genotype (i-T744T) of P2Y12
receptor and heterozygous genotype (G681A) of CYP2C19*2.
Further Malek et al32 have reported that the carriers of i-744C
allele of P2Y12without variant allele of CYP2C19*2 did not have
significantly decreased platelet response to ADP suggesting
that i-T744C polymorphism of P2Y12 could also independently
elevate platelet reactivity. In the present study we had only
one case with homozygous mutant (i-C744C) genotype of
P2Y12 and wild type of CYP2C19*2 which was also associated
with increased response to ADP with PAI of only 11% at 24 h.
Small study population for analyzing the platelet aggre-
gation effect is the major limitation of our study which was
further affected by variations in genotypes. To see the extentof clopidogrel to inhibit the platelet aggregation, it was very
important that these patients were without any prior anti-
platelet intake. For this reason, patients with prior antiplatelet
treatment were excluded and these 26 AMI clopidogrel naı¨ve
patients were screened from 100 AMI patients in the span of
two years from January 2009 to March 2011.5. Conclusion
In our study the occurrence of variant alleles ofMDR1 (3435T),
CYP2C19*2 (681A), P2Y12 (i-744C) as well as wild type allele of
CYP2C19*17 (C806) associated with decreased clopidogrel
response were observed. The present study did show a trend
toward impaired response of clopidogrel to inhibit platelet
aggregation with variant genotypes of CYP2C19*2 and iT744C
of P2Y12 compared to respective wild type genotype at 24 h.
Similar studies of larger sample size and of longer follow-up
may strengthen our view for individualized antiplatelet
treatment based on genotypic analysis for patients with ACS
and those undergoing PCI who receive loading dose of 300 mg
of clopidogrel.Funding source
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